CEDRA: A Tool to Help Consumers Assess Risk for Ear Disease

Niall A.M. Klyn, Samantha Kleindienst Robler, Jamie Bogle, Razan Alfakir, Donald W. Nielsen, James W. Griffith, Deborah L. Carlson, Larry Lundy, Sumitrajit Dhar, David A. Zapala

Research output: Contribution to journalArticle

Abstract

This article introduces the Consumer Ear Disease Risk Assessment (CEDRA) tool. CEDRA is a brief questionnaire designed to screen for targeted ear diseases. It offers an opportunity for consumers to self-screen for disease before seeking a hearing device and may be used by clinicians to help their patients decide the appropriate path to follow in hearing healthcare. Here we provide highlights of previously published validation in the context of a more thorough description of CEDRA's development and implementation. CEDRA's sensitivity and specificity, using a cut-off score of 4 or higher, was 90% and 72%, respectively, relative to neurotologist diagnoses in the initial training sample used to create the scoring algorithm (n = 246). On a smaller independent test sample (n = 61), CEDRA's sensitivity and specificity were 76% and 80%, respectively. CEDRA has readability levels similar to many other patient-oriented questionnaires in hearing healthcare, and informal reports from pilot CEDRA-providers indicate that the majority of patients can complete it in less than 10 min. As the hearing healthcare landscape changes and provider intercession is no longer mandated, CEDRA provides a measure of safety without creating a barrier to access.

Original languageEnglish (US)
Pages (from-to)1261-1266
Number of pages6
JournalEar and hearing
Volume40
Issue number6
DOIs
StatePublished - Nov 1 2019

Fingerprint

Ear Diseases
Hearing
Delivery of Health Care
Sensitivity and Specificity
Safety
Equipment and Supplies

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Speech and Hearing

Cite this

Klyn, N. A. M., Kleindienst Robler, S., Bogle, J., Alfakir, R., Nielsen, D. W., Griffith, J. W., ... Zapala, D. A. (2019). CEDRA: A Tool to Help Consumers Assess Risk for Ear Disease. Ear and hearing, 40(6), 1261-1266. https://doi.org/10.1097/AUD.0000000000000731
Klyn, Niall A.M. ; Kleindienst Robler, Samantha ; Bogle, Jamie ; Alfakir, Razan ; Nielsen, Donald W. ; Griffith, James W. ; Carlson, Deborah L. ; Lundy, Larry ; Dhar, Sumitrajit ; Zapala, David A. / CEDRA : A Tool to Help Consumers Assess Risk for Ear Disease. In: Ear and hearing. 2019 ; Vol. 40, No. 6. pp. 1261-1266.
@article{f30804ba7a6449018f6adea4d571684b,
title = "CEDRA: A Tool to Help Consumers Assess Risk for Ear Disease",
abstract = "This article introduces the Consumer Ear Disease Risk Assessment (CEDRA) tool. CEDRA is a brief questionnaire designed to screen for targeted ear diseases. It offers an opportunity for consumers to self-screen for disease before seeking a hearing device and may be used by clinicians to help their patients decide the appropriate path to follow in hearing healthcare. Here we provide highlights of previously published validation in the context of a more thorough description of CEDRA's development and implementation. CEDRA's sensitivity and specificity, using a cut-off score of 4 or higher, was 90{\%} and 72{\%}, respectively, relative to neurotologist diagnoses in the initial training sample used to create the scoring algorithm (n = 246). On a smaller independent test sample (n = 61), CEDRA's sensitivity and specificity were 76{\%} and 80{\%}, respectively. CEDRA has readability levels similar to many other patient-oriented questionnaires in hearing healthcare, and informal reports from pilot CEDRA-providers indicate that the majority of patients can complete it in less than 10 min. As the hearing healthcare landscape changes and provider intercession is no longer mandated, CEDRA provides a measure of safety without creating a barrier to access.",
author = "Klyn, {Niall A.M.} and {Kleindienst Robler}, Samantha and Jamie Bogle and Razan Alfakir and Nielsen, {Donald W.} and Griffith, {James W.} and Carlson, {Deborah L.} and Larry Lundy and Sumitrajit Dhar and Zapala, {David A.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/AUD.0000000000000731",
language = "English (US)",
volume = "40",
pages = "1261--1266",
journal = "Ear and Hearing",
issn = "0196-0202",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Klyn, NAM, Kleindienst Robler, S, Bogle, J, Alfakir, R, Nielsen, DW, Griffith, JW, Carlson, DL, Lundy, L, Dhar, S & Zapala, DA 2019, 'CEDRA: A Tool to Help Consumers Assess Risk for Ear Disease', Ear and hearing, vol. 40, no. 6, pp. 1261-1266. https://doi.org/10.1097/AUD.0000000000000731

CEDRA : A Tool to Help Consumers Assess Risk for Ear Disease. / Klyn, Niall A.M.; Kleindienst Robler, Samantha; Bogle, Jamie; Alfakir, Razan; Nielsen, Donald W.; Griffith, James W.; Carlson, Deborah L.; Lundy, Larry; Dhar, Sumitrajit; Zapala, David A.

In: Ear and hearing, Vol. 40, No. 6, 01.11.2019, p. 1261-1266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CEDRA

T2 - A Tool to Help Consumers Assess Risk for Ear Disease

AU - Klyn, Niall A.M.

AU - Kleindienst Robler, Samantha

AU - Bogle, Jamie

AU - Alfakir, Razan

AU - Nielsen, Donald W.

AU - Griffith, James W.

AU - Carlson, Deborah L.

AU - Lundy, Larry

AU - Dhar, Sumitrajit

AU - Zapala, David A.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - This article introduces the Consumer Ear Disease Risk Assessment (CEDRA) tool. CEDRA is a brief questionnaire designed to screen for targeted ear diseases. It offers an opportunity for consumers to self-screen for disease before seeking a hearing device and may be used by clinicians to help their patients decide the appropriate path to follow in hearing healthcare. Here we provide highlights of previously published validation in the context of a more thorough description of CEDRA's development and implementation. CEDRA's sensitivity and specificity, using a cut-off score of 4 or higher, was 90% and 72%, respectively, relative to neurotologist diagnoses in the initial training sample used to create the scoring algorithm (n = 246). On a smaller independent test sample (n = 61), CEDRA's sensitivity and specificity were 76% and 80%, respectively. CEDRA has readability levels similar to many other patient-oriented questionnaires in hearing healthcare, and informal reports from pilot CEDRA-providers indicate that the majority of patients can complete it in less than 10 min. As the hearing healthcare landscape changes and provider intercession is no longer mandated, CEDRA provides a measure of safety without creating a barrier to access.

AB - This article introduces the Consumer Ear Disease Risk Assessment (CEDRA) tool. CEDRA is a brief questionnaire designed to screen for targeted ear diseases. It offers an opportunity for consumers to self-screen for disease before seeking a hearing device and may be used by clinicians to help their patients decide the appropriate path to follow in hearing healthcare. Here we provide highlights of previously published validation in the context of a more thorough description of CEDRA's development and implementation. CEDRA's sensitivity and specificity, using a cut-off score of 4 or higher, was 90% and 72%, respectively, relative to neurotologist diagnoses in the initial training sample used to create the scoring algorithm (n = 246). On a smaller independent test sample (n = 61), CEDRA's sensitivity and specificity were 76% and 80%, respectively. CEDRA has readability levels similar to many other patient-oriented questionnaires in hearing healthcare, and informal reports from pilot CEDRA-providers indicate that the majority of patients can complete it in less than 10 min. As the hearing healthcare landscape changes and provider intercession is no longer mandated, CEDRA provides a measure of safety without creating a barrier to access.

UR - http://www.scopus.com/inward/record.url?scp=85074117896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074117896&partnerID=8YFLogxK

U2 - 10.1097/AUD.0000000000000731

DO - 10.1097/AUD.0000000000000731

M3 - Article

C2 - 30946136

AN - SCOPUS:85074117896

VL - 40

SP - 1261

EP - 1266

JO - Ear and Hearing

JF - Ear and Hearing

SN - 0196-0202

IS - 6

ER -

Klyn NAM, Kleindienst Robler S, Bogle J, Alfakir R, Nielsen DW, Griffith JW et al. CEDRA: A Tool to Help Consumers Assess Risk for Ear Disease. Ear and hearing. 2019 Nov 1;40(6):1261-1266. https://doi.org/10.1097/AUD.0000000000000731